Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01637961 · OUTCOME

Overall Survival

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From study entry to death or last contact, up to 5 years.

What was measured

The observed length of life from entry into the study to death or the date of last contact.

Analysis population: Eligible and treated patients.

Groups in this outcome

MLN8237

MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MLN823721

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
MLN823713.6Not reported5.6517.28Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.65
        upper Limit
        17.28
        value
        13.6
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    units
    Participants
description
The observed length of life from entry into the study to death or the date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.
    id
    OG000
    title
    MLN8237
param Type
MEDIAN
population Description
Eligible and treated patients.
reporting Status
POSTED
time Frame
From study entry to death or last contact, up to 5 years.
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice